Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

5.8K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

580
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
580
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

944
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
944
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

13.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.3K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

8.6K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
8.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influence of feeding habit and duration on infant gut microbiome - a 6 month pilot study.

Beneficial microbes·2025
Same author

Proteomic and metabolomic profiles of plasma-derived Extracellular Vesicles differentiate melanoma patients from healthy controls.

Translational oncology·2024
Same author

Widespread service fragmentation for patients and families with tuberous sclerosis complex (TSC) in the Republic of Ireland.

Journal of rare diseases (Berlin, Germany)·2024
Same author

The incremental yield of prenatal exome sequencing over chromosome microarray for congenital heart abnormalities: A systematic review and meta-analysis.

Prenatal diagnosis·2024
Same author

The development and acceptability of an educational and training intervention for recruiters to neonatal trials: the TRAIN project.

BMC medical research methodology·2023
Same author

Surgical removal of a jugular aneurysm in a spaniel cross dog.

The Journal of small animal practice·2023

Related Experiment Video

Updated: Feb 25, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis.

R Reilly1, M S Mroz2, E Dempsey3

  • 1Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland.

Scientific Reports
|August 11, 2017
PubMed
Summary

Targeting the PI3K/Akt/mTOR pathway can restore autophagy and improve cystic fibrosis transmembrane conductance regulator (CFTR) expression in cystic fibrosis (CF) cells. This offers a promising therapeutic strategy for CF treatment.

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

979

Related Experiment Videos

Last Updated: Feb 25, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

979

Area of Science:

  • Cell Biology
  • Molecular Medicine
  • Genetics

Background:

  • Cystic fibrosis (CF) is primarily caused by the ΔF508 CFTR mutation, leading to protein misfolding and ER retention.
  • Developing treatments to improve ΔF508 CFTR trafficking from the endoplasmic reticulum (ER) is crucial for CF therapy.

Purpose of the Study:

  • To investigate the association between mammalian target of rapamycin (mTOR) signaling and ΔF508 CFTR.
  • To evaluate the therapeutic potential of inhibiting the PI3K/Akt/mTOR pathway for CF.

Main Methods:

  • Protein interaction profiling and bioinformatics analysis to identify signaling pathways linked to ΔF508 CFTR.
  • Utilizing six different PI3K/Akt/mTOR inhibitors on ΔF508 CF bronchial epithelial cells (CFBE41o-).
  • Investigating the role of autophagy and Bcl-2-associated athanogene 3 (BAG3) in the therapeutic mechanism.

Main Results:

  • Upregulated mTOR activity was observed in ΔF508 CFBE41o- cells.
  • Inhibition of the PI3K/Akt/mTOR pathway increased CFTR stability and expression.
  • The inhibitor MK-2206 restored autophagy and potentially targeted BAG3, improving cellular function.

Conclusions:

  • The PI3K/Akt/mTOR pathway is implicated in CFTR trafficking defects.
  • Targeting this pathway, particularly with autophagy restoration, presents a viable therapeutic avenue for cystic fibrosis.